Drug intelligence / Profile preview

DMX-2001

Development stage: Preclinical
Lead developer: DemeRx
Modality: Small Molecules
Administration: Oral

Overview

DMX-2001 is a preclinical-stage small molecule drug candidate being developed by DemeRx for the treatment of substance use disorders. It belongs to the ampakine class of compounds, which are designed to act as positive allosteric modulators of the AMPA-type glutamate receptor. By enhancing glutamatergic signaling and synaptic plasticity, DMX-2001 aims to address the underlying neurobiological mechanisms associated with addiction and substance misuse. As of early 2026, the program remains in the preclinical phase of development.

Other names: Ampakines

Targets

AMPAR (AMPA receptor)

Beyond the preview

Go deeper on DMX-2001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DMX-2001.

Explore the full profile